GlassScriptPhysician profile
Anna Maria De Costa
NPI 1407261522
$1,435.27
in general payments reported to CMS, 2019-2025
27 companies · $1,040 in 2025
The $1,040 reported for 2025 was more than what 84% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55.81 · 2021: $42.02 · 2022: $11.27 · 2023: $72.66 · 2024: $214 · 2025: $1,040.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,326.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $327.84 | 2024-2025 | |
| Exelixis INC. | $115.00 | 2025 | Cabometyx |
| Boston Scientific Corporation | $107.32 | 2019-2024 | Spaceoar System |
| Janssen Biotech, INC. | $79.23 | 2025 | Talvey, Tecvayli, Rybrevant |
| Daiichi Sankyo INC. | $70.98 | 2024-2025 | Enhertu, Datroway |
| Incyte Corporation | $69.06 | 2025 | Jakafi, Monjuvi, Zynyz |
| Astrazeneca Pharmaceuticals LP | $67.52 | 2021-2025 | Imfinzi, Calquence |
| Sumitomo Pharma America, INC. | $57.87 | 2023-2024 | Orgovyx |
| Abbvie INC. | $53.86 | 2025 | |
| Geron Corporation | $45.03 | 2025 | Rytelo |
| Novocure INC. | $44.19 | 2023-2025 | Optune Gio, Optune |
| Sobi, INC | $42.61 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.75 | 2025 | Fruzaqla |
| Genzyme Corporation | $35.30 | 2025 | |
| Jazz Pharmaceuticals INC. | $27.86 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $27.66 | 2025 | Keytruda |
| Genmab U.S., INC. | $27.19 | 2024 | Epkinly |
| Bayer Healthcare Pharmaceuticals INC. | $24.99 | 2025 | |
| Karyopharm Therapeutics INC. | $24.47 | 2025 | Xpovio |
| Carl Zeiss Meditec USA, INC. | $23.29 | 2023 | Artevo 800 |
| Stemline Therapeutics INC. | $22.54 | 2025 | Orserdu |
| Celgene Corporation | $22.29 | 2025 | Reblozyl |
| Tersera Therapeutics LLC | $21.70 | 2025 | Zoladex |
| Pfizer INC. | $19.70 | 2025 | |
| Adaptive Biotechnologies Corporation | $16.11 | 2025 | Clonoseq |
| Puma Biotechnology, INC. | $13.64 | 2025 | |
| Myriad Genetic Laboratories, INC. | $11.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Maria De Costa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.